Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | +1.35% | -7.11% | -57.12% |
Financials (USD)
Sales 2024 * | 600K | Sales 2025 * | 600K | Capitalization | 7.58M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -31M | EV / Sales 2024 * | 12.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
-0.41
x | P/E ratio 2025 * |
-0.4
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.12% |
Latest transcript on TFF Pharmaceuticals, Inc.
1 day | +1.35% | ||
1 week | -7.11% | ||
Current month | -50.17% | ||
1 month | -60.86% | ||
3 months | -43.21% | ||
6 months | -64.55% | ||
Current year | -57.12% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Kirk Coleman
DFI | Director of Finance/CFO | 51 | 18-01-23 |
Zamaneh Mikhak
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 18-11-30 | |
Brandi Roberts
BRD | Director/Board Member | 50 | 22-03-24 |
Thomas King
BRD | Director/Board Member | 69 | Dec. 12 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 3.01 | +1.35% | 12,712 |
24-04-23 | 2.97 | +15.12% | 62,771 |
24-04-22 | 2.58 | -17.04% | 47,266 |
24-04-19 | 3.11 | -0.80% | 3,671 |
24-04-18 | 3.135 | -3.26% | 26,484 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.12% | 7.48M | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- TFFP Stock